International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)
Predicts overall and progression-free survival in DLBCL based on risk factors.
Note: IPI results are included for historical comparisons only. Use in CD20+ DLBCL patients. Do not use in patients with HIV, secondary malignancies, low grade lymphoproliferative disorders, or comorbidities precluding curative therapy attempt.
When to Use
Please fill out required fields.
Have feedback about this calculator?